Introduction: Baseline severity and clinical stroke syndrome (Oxford Community
INTRODUCTION
Baseline stroke severity, as assessed using measures such as Scandinavian Neurological Stroke Scale (SNSS) 1, 2 or National Institute Health Stroke Scale (NIHSS), 3 4 is widely accepted as the strongest clinical predictor of outcome in stroke;
severe stroke is associated with an increased risk of death, disability and length of hospital stay, and institutionalisation. 3, 5-8 9 Similarly, severity, is also related to the early clinical course, with patients with severe stroke more likely to experience deterioration. 10 In addition, recovery is observed later in severe stroke 11 and it has been postulated that the extent of intrinsic cerebral damage is reflected not only by the degree of impairment, but also in the length of time to improvement after stroke. 12 The importance of clinical history and examination, for evaluating stroke patients is well recognised, 13 and stroke can be classified into four clinical syndromes, which have distinct natural histories: total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), lacunar syndrome (LACS) and posterior circulation syndrome (POCS). TACS is typically associated with greatest severity and worse outcome, PACS the highest risk of recurrence, whilst LACS has the mildest severity, and POCS the most favourable outcome. 14 Clinical classification is also predictive of the risk of deterioration, with TACS having the greatest risk and LACS the least; deterioration is associated with a worse prognosis. 15 The relationship between clinical classification and degree and timing of stroke recovery is less clear, and has been further examined here using data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST). 16 
METHODS

Subjects
TAIST compared the safety and efficacy of tinzaparin (low molecular weight heparin)
given at high dose (175 anti-Xa IU/kg/day), tinzaparin at medium dose (100 anti-Xa IU/kg/day), and aspirin (300 mg od), in patients with acute ischaemic stroke.
Subjects were included within 48 hours of stroke onset. Non-trial anti-platelets or anti-coagulants could not be given during the treatment period (10 days).
Management of hypertension and other factors such as carotid stenosis was at the discretion of the local physician. All data were collected prospectively as part of the trial protocol.
Clinical stroke classification
Investigators prospectively recorded baseline clinical stroke syndrome as part of the trial protocol, and used the Oxford Community Stroke Project (OCSP) classification.
14 All patients had haemorrhagic stroke excluded on the basis of computed topographic (CT) head scan and therefore were classified as total anterior circulation infarct (TACI), partial anterior circulation infarct (PACI), lacunar infarct (LACI) and posterior circulation infarct (POCI).
Recovery
Severity/impairment was measured at four different time points: baseline, day 4, 7 and 10 using the Scandinavian Neurological Stroke Scale (SNSS), which ranges from 0 (most severe) to 58 (no deficit), with death recorded as -1. The rate of recovery was calculated as the change in SNSS at each time point. For comparison, patients were split into two groups: those who improved early (improvement ≥3 on SNSS between baseline and day 4); and those who did not; 3 points was chosen as this was the median change in SNSS at day 4. Day 4 was chosen as the largest change in SNSS occurred between baseline and day 4 and those with day 4 SNSS score missing were not categorised..
Outcomes
Outcome was assessed using the modified Rankin Scale (mRS) and Barthel Index (BI)
at day 90 and recorded by face-to-face interview. Discharge disposition was classified as patients own home or other (such as institution).
Events
Adverse events were recorded prospectively as part of the trial protocol including neurological deterioration (ND, a decrease in SNSS ≥ 5 points), recurrent stroke (RS, either ischaemic, haemorrhagic or unclassified), venous thromboembolism (deep vein thrombosis and/or pulmonary embolism), and extracranial bleeding. Other events, such as pneumonia, and cardiac events (myocardial syndrome, dysrhythmia) were also recorded. Event rates at day 4 were analysed pooled for clinical classification and then by early improvers and non improvers. Whilst some patients had more than one adverse event, the categories ND, RS and HTI were considered exclusive.
Statistical methods
Data are given as frequency (%), mean (standard deviation) or median (interquartile range) as appropriate. Patient characteristics and prognostic factors were compared by OCSP subgroup, using Chi-square, Wilcoxon and t-tests. Area under the curve (AUC) was used to compare the patterns of recovery by group. Change in SNSS was calculated at each time point and compared using Kruskal-Wallis Test. The Wilcoxon test was used to compare outcome in those who improved early with those who did not within each OCSP group. All analyses were performed using SAS (SAS Inst., USA).
Significance was taken at p<0.05 and 95% confidence intervals are given.
RESULTS
Subjects
Of 1,499 randomised patients, emerging exclusion criteria prevented treatment in 15, with analyses performed on the remaining 1,484 patients (figure 1). The baseline characteristics of included patients are shown in table 1. Similar numbers of patients had TACI and PACI, whilst few had a POCI. Those with POCI tended to be slightly younger, and TACI patients were older and more likely to be male. There was a higher frequency of atrial fibrillation in patients with TACI, whilst patients with LACI had increased frequency of diabetes, and baseline blood pressure was also the highest (table 1) . Patients with TACI had the most severe stroke severity (median SNSS 22) and LACI the least (median SNSS 40).
Recovery
Stroke impairment differed significantly between TACI (most severe), PACI and POCI notably patients with TACI who improve by day 4 still had a comparable day 10 SNSS score to those PACI, LACI or POCI who had not improved (figure 2b). After day 4, there was no difference between clinical subgroups in the rate of recovery observed.
Outcome
The modified Rankin Scale and Barthel Index differed significantly between TACI and the other stroke syndromes, in both improvers and non-improvers (table 3) .
Improvers in each clinical group had a significantly better outcome at day 90 compared to those who had not improved at day 4. These differences persisted after adjustment for age. Notably, TACI improvers had similar outcomes to PACI, POCI and LACI, who had not improved (table 3) . Improvers were significantly more likely to be discharged home (81.5%) than non-improvers (66.3%) (p<0.001).
Adverse Events
Neurological deterioration (ND) and recurrent stroke (RS, ischaemic or haemorrhagic)
events were confined to non-improvers at day 4, whilst other events (such as cardiac events and VTE) occurred in both improvers and non-improvers (table 4) .
Deterioration occurred more frequently than recurrence; TACI patients had the highest frequency of both ND and RS in comparison to patients with LACI who had the lowest frequency (table 4) . Similarly, patients with TACI had the highest rate of any adverse event whilst LACI had the lowest.
DISCUSSION
In keeping with previous studies we have demonstrated that baseline severity varies between clinical stroke syndromes, being mildest in LACI and most severe in patients with TACI. That this difference in severity persists throughout the first 10 days post stroke has not been previously described. Perhaps unsurprisingly, the rate of recovery also varies between syndromes, again with LACI improving most and fastest and TACI least and slowest.
In the first ten days, most recovery occurred early (by day 4), following which time recovery was more linear. 6, 17 We therefore dichotomised patients into 'improvers' and 'non-improvers', dependent on their rate of recovery at day 4, and the recovery patterns of these sub-groups were distinct from one another. Furthermore, early improvement was significantly associated with a good outcome. Spontaneous recovery and association with good outcome is well documented in stroke [17] [18] [19] although in comparison to this group of patients, previous studies included either only moderate 19 or very severe stroke. 19 The relationship between early improvement and outcome, across the range of stroke severity studied here, in patients within each clinical syndrome has not previously been documented. Furthermore the changes seen here were modest (median change ≥ 3 SNSS points) yet were still associated with a clinically significant improvement in outcome.
Unlike aetiological classification, which is dependent on the results of ancillary investigations, 20 clinical classification is simple and can be performed with reasonable reliability on initial assessment of the patient. 21 Similarly, the further assessment of impairment as a measure of recovery during the first week after stroke can strengthen ability to predict outcome. 22 This makes the combination of clinical classification and monitoring of recovery an attractive tool, both clinically and for research where the ability to accurately predict recovery and outcome is key. This may be especially beneficial in subgroups of patients thought typically to have a poorer outcome, such as TACS, since there appears that there is at least one subgroup of patients who may do relatively well.
Potential reasons for non improvement were analysed and were insufficient to account for lack of improvement in the majority of patients. However, recovery mechanisms are poorly understood and may relate to angiological factors, including spontaneous lysis, thrombus migration and transcortical perfusion networks, 23 which were not studied directly here. Beyond these vascular factors, recover may also be intrinsically linked to the brain's plastic potential, 24 not withstanding that certain events may intervene and prevent recovery.
A caveat in our findings is that by assessing recovery in terms of severity (SNSS), multivariate analysis was not possible to ascertain if outcome was related to severity, as has been previously well documented. Furthermore, selection bias may have been present since we studied patients enrolled into the randomised trial; limited inclusion criteria will mean that some groups of patients were under represented (e.g. POCI)
whilst the trial excluded patients with very minor or very severe strokes. Similarly, due to the long recruitment time window in TAIST (48 hours), stroke impairment will have changed in some patients prior to enrolment, and also patients who may have improved or deteriorated rapidly during the first hours will have been excluded. Future studies should focus on patients with hyperacute stroke. Despite this a large number of patients continue to present late to medical practitioners. Finally, limitations of clinical classification are well documented, 21 with concordance for the diagnosis of PACS less than for that for TACS and LACS. 25 Despite these points, TAIST contains high quality data on a large number of patients in a population where no treatment effect was observed, hence making it appropriate for hypothesis generating analyses. This study suggests that early recovery is related to clinical stroke syndrome, with LACI having the greatest recovery and most favourable outcome, and TACI having the least recovery and poorest outcome.
However, significant recovery can occur in patients traditionally thought to have a poor prognosis, such as TACI and PACI, with clinically significant improvement in outcome.
These data, if confirmed, suggest that early monitoring of recovery using a simple clinical classification and impairment scale such as OCSP and SNSS respectively, may help in predicting prognosis and possibly deciding which patients to recruit into trials. 
